Skip to main content
Fig. 1 | BMC Medical Informatics and Decision Making

Fig. 1

From: The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study)

Fig. 1

The study flow chart. Note: for patients who relapse during follow up, the study treatments will be stopped and patients will be referred to appropriate alternative treatments and follow up will be continued for cost data collection. RA: Rheumatoid Arthritis; csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs; MTX: methotrexate; HCQ: hydroxychloroquine; SSZ: sulfasalazine; TNFi: Tumor necrosis factor α inhibitors; CR:clinical remission; LDA: low disease activity

Back to article page

BMC Medical Informatics and Decision Making

ISSN: 1472-6947

Contact us